POSTMENOPAUSAL OSTEOPOROSIS

绝经后骨质疏松症

• 批准号: 6265511
• 负责人: NORMAN L BELL
• 金额: $ 1.74万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6265511
• 关键词: alendronate; calcitonin; clinical research; drug adverse effect; drug screening /evaluation; female; human subject; human therapy evaluation; osteoporosis; postmenopause; skeletal disorder chemotherapy; women's health

This study is designed to compare the effectiveness of two medications. Fosamax (alendronate sodium tablets) and Miacalcin (calcitonin-salmon) Nasal Spray. Currently prescribed in the United States for treatment of postmenopausal osteoporosis, and to assess safety and tolerability of their treatments. All patients will also receive Vitamin D and calcium supplements, if needed. Calcium is an essential nutrient for healthy bones; many clinical studies have shown that increasing calcium intake may protect the skeleton from further bone loss. Approximately 320 postmenopausal women will be entered into this study.

这项研究旨在比较两种药物的有效性。Fosamax（阿仑膦酸钠片）和Miacalcin（降钙素鲑鱼）鼻喷雾剂。 目前在美国用于治疗绝经后骨质疏松症，并评估其治疗的安全性和耐受性。 如果需要，所有患者还将接受维生素D和钙补充剂。 钙是健康骨骼的必需营养素;许多临床研究表明，增加钙的摄入量可以保护骨骼免受进一步的骨质流失。 约320名绝经后女性将入组本研究。